Table 6.
Genotypes of 8 SNPs of FGFR gene and their associations with adverse events
| Target Gene | Polymorphisms/Genotype | Toxicity(grade 3–4) N = 102(48%) |
No toxicity (grade1–2) N = 109(52%) |
OR (95%CI) | P | P HWE |
|---|---|---|---|---|---|---|
| FGFR1 | rs2288696 | 0.035 | ||||
| C/C | 85(83.3%) | 88(80.7%) | Reference | |||
| C/T | 14(13.7%) | 19(17.4%) | 0.76(0.36—1.62) | 0.480 | ||
| T/T | 3(2.9%) | 2(1.8%) | 1.55(0.25—9.53) | 0.634 | ||
| Dominat model | 17(16.7%) | 21(19.3%) | 0.84(0.41—1.70) | 0.624 | ||
| Recessive model | 99(97.1%) | 107(98.2%) | 0.62(0.10—3.77) | 0.601 | ||
| Alleles | ||||||
| C | 184(90.2%) | 195(89.4%) | Reference | |||
| T | 20(9.8%) | 23(10.6%) | 0.92(0.49—1.73) | 0.800 | ||
| FGFR2 | rs2981582 | 0.138 | ||||
| C/C | 52(51.0%) | 47(43.1%) | Reference | |||
| C/T | 37(36.3%) | 47(43.1%) | 0.71(0.40—1.28) | 0.253 | ||
| T/T | 13(12.7%) | 15(13.8%) | 0.78(0.34—1.82) | 0.569 | ||
| Dominat model | 50(49.0%) | 62(56.9%) | 0.73(0.42—1.25) | 0.253 | ||
| Recessive model | 89(87.3%) | 94(86.2%) | 1.09(0.49—2.43) | 0.828 | ||
| Alleles | ||||||
| C | 141(69.1%) | 141(64.7%) | Reference | |||
| T | 63(30.9%) | 77(35.3%) | 0.82(0.55—1.30) | 0.333 | ||
| rs1219648 | 0.726 | |||||
| A/A | 34(33.3%) | 33(30.3%) | Reference | |||
| A/G | 49(48.0%) | 57(52.3%) | 0.83(0.45—1.54) | 0.562 | ||
| G/G | 19(18.6%) | 19(17.4%) | 0.97(0.44—2.15) | 0.941 | ||
| Dominat model | 68(66.7%) | 76(69.7%) | 0.87(0.49—1.55) | 0.634 | ||
| Recessive model | 83(81.4%) | 90(82.6%) | 0.92(0.46—1.86) | 0.821 | ||
| Alleles | ||||||
| A | 117(57.4%) | 123(56.4%) | Reference | |||
| G | 87(42.6%) | 95(43.6%) | 0.96(0.66—1.42) | 0.847 | ||
| rs2420946 | 0.172 | |||||
| T/T | 13(12.7%) | 22(20.2%) | Reference | |||
| C/T | 39(38.2%) | 51(46.8%) | 1.29(0.58—2.89) | 0.529 | ||
| C/C | 50(49.0%) | 36(33.0%) | 2.35(1.05—5.28) | 0.038* | ||
| Dominat model | 89(87.3%) | 87(79.8%) | 1.73(0.82—3.65) | 0.150 | ||
| Recessive model | 52(51.0%) | 73(67.0%) | 0.51(0.29—0.90) | 0.019* | ||
| Alleles | ||||||
| T | 65(31.9%) | 95(43.6%) | Reference | |||
| C | 139(68.1%) | 123(56.4%) | 1.65(1.11—2.46) | 0.013* | ||
| rs2981579 | 0.196 | |||||
| T/T | 29(28.4%) | 25(22.9%) | Reference | |||
| C/T | 38(37.3%) | 58(53.2%) | 0.57(0.29—1.11) | 0.096 | ||
| C/C | 35(34.3%) | 26(23.9%) | 1.16(0.56—2.43) | 0.692 | ||
| Dominant model | 73(71.6%) | 84(77.1%) | 0.75(0.40—1.39) | 0.361 | ||
| Recessive model | 67(65.7%) | 83(76.1%) | 0.60(0.33—1.09) | 0.095 | ||
| Alleles | ||||||
| T | 96(47.1%) | 108(49.5%) | Reference | |||
| C | 108(52.9%) | 110(50.5%) | 1.11(0.75—1.62) | 0.610 | ||
| rs2981578 | 0.909 | |||||
| G/G | 30(29.4%) | 70(64.2%) | Reference | |||
| A/G | 61(59.8%) | 29(26.6) | 4.91(2.65—9.08) | < 0.0001* | ||
| A/A | 11(10.8%) | 10(9.1%) | 2.57(0.99—6.69) | 0.054 | ||
| Dominant model | 72(70.6%) | 39(35.8%) | 2.57(0.99–6.69) | < 0.0001* | ||
| Recessive model | 91(89.2%) | 99(90.8%) | 0.84(0.34–2.06) | 0.697 | ||
| Alleles | ||||||
| G | 121(59.3%) | 169(82.8%) | Reference | |||
| A | 83(40.7%) | 49(24.0%) | 2.37(1.55—3.61) | < 0.0001* | ||
| FGFR3 | rs743682 | 0.682 | ||||
| G/G | 85(83.3%) | 92(84.4%) | Reference | |||
| A/G | 15(14.7%) | 17(15.6%) | 0.96(0.45—2.03) | 0.955 | ||
| A/A | 2(2.0%) | 0 | 0.00 | 0.999 | ||
| Dominant model | 17(16.7%) | 17(15.6%) | 1.08(0.52—2.26) | 0.833 | ||
| Recessive model | 100(98.0%) | 109(100.0%) | 0.00 | 0.999 | ||
| Alleles | ||||||
| G | 185(90.7%) | 201(92.2%) | Reference | |||
| A | 19(9.3%) | 17(7.8%) | 1.21(0.61—2.41) | 0.578 | ||
| FGFR4 | rs1966265 | 0.998 | ||||
| G/G | 22(21.6%) | 19(17.4%) | Reference | |||
| A/G | 46(45.1%) | 58(53.2%) | 0.69(0.33—1.42) | 0.307 | ||
| A/A | 34(33.3%) | 32(29.4%) | 0.92(0.42—2.00) | 0.829 | ||
| Dominant model | 80(78.4%) | 90(82.6%) | 0.77(0.39—1.52) | 0.449 | ||
| Recessive model | 68(66.7%) | 77(70.6%) | 0.83(0.46—1.49) | 0.534 | ||
| Alleles | ||||||
| G | 90(44.1%) | 96(44. %) | Reference | |||
| A | 114(55.9%) | 122(56.0%) | 1.00(0.68—1.46) | 0.987 |
OR odds ratio, 95% CI 95% confidence interval, * A P value < 0.05 was considered ststistically significant